Last Updated on December 30, 2021 by The Health Master
Granules India today said it has received approval from the US health regulator for its generic Prazosin Hydrochloride capsules used for the treatment of high blood pressure.
The US Food and Drug Administration (USFDA) granted approval to the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc. (GPI).
This is a wholly-owned foreign subsidiary of the company — for Prazosin Hydrochloride capsules, of strengths 1mg, 2mg and 5mg, Granules India said in a statement.
These capsules are bioequivalent to the reference listed drug product, Mini Plus Capsules 1mg, 2mg, and 5mg of Pfizer Inc, it said, adding the product would be available for the US market shortly.
Citing IQVIA/IMS Health data, the company said the current annual US market for Prazosin Hydrochloride 1mg, 2mg, and 5mg strengths is approximately $54 million.
USFDA gives nod to Lupin for this drug to treat Kidney disease
USFDA gives nod to Lupin generic Azilsartan Medoxomil tablets
USFDA authorises first oral antiviral to treat COVID
USFDA approves expanded use of Amgen’s psoriasis drug
USFDA gives nod to Cipla for Lanreotide injection
USFDA gives Orphan Drug Designation to Zydus for malaria treatment
E-pharmacies, Telemedicine to help cut health expenses
Won’t allow drug peddlers to ruin lives of youth: HM
What is ‘Delmicron’ ? Is it a cause of concern?
Hospital fined Rs 50,000 over waste disposal
Side-Effect of Ibuprofen – Painful Skin Disorders: India to act soon
CDSCO panel weighing risks and benefits of Covid drug Molnupiravir
5 reasons why e-Rx (electronic prescription) is better than paper Rx
Schedule for 19 FDCs permitted pre-1988 to give online presentation
Drug alert: 22 out of 1102 samples declared as NSQ in…
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon: